SecBot SecBot
8-K ·Filed Nov 12, 2026

SPRO

Spero Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 7h ago SEC0001193125-26-458637
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The company is now a pre-revenue clinical-stage biotech focused on SP001. Key catalysts are Phase 2 initiation in IgG4-RD (Q2 2027) and any future milestone payments from GSK on tebipenem HBr. Cash runway into H2 2029 provides a long development horizon.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SPRO drug pipeline →

SP001

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2-ready (Phase 1 completed in healthy volunteers and Sjögren's disease)
Time to market
5+ years (Phase 2 starting Q2 2027; IgG4-RD is an orphan indication but still requires Phase 2 and Phase 3)
Next catalyst
None dated

What to watchSP001 is a new pipeline asset for Spero, announced alongside a $105M non-dilutive royalty financing from Utebzi sales. Watch for the Phase 2 initiation in IgG4-RD (Q2 2027) as the next catalyst. The stock may re-rate on execution towards Phase 2 start, but the $1.1B milestone burden relative to Spero's ~$126M market cap is a significant overhang. Monitor Innovent's Phase 2 SjD data in China (early 2027) as a read-through for the mechanism.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.9999
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.35%
T+1 · $0.9464
Vs SPY
−3.44%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.9999entry
  2. T+1 · 17h ago −5.35%α −3.44% · $0.9464
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76 per share), compared to $5.4 million revenue and a $7.4 million loss in Q3 2025. The wider loss reflects a $35 million upfront payment to Innovent for in-licensing SP001, a Phase 2-ready anti-CD40L antibody for IgG4-related disease. Cash of $107.9 million funds operations into H2 2029, and the company has shifted focus from tebipenem HBr (now partnered with GSK) to immune-mediated diseases.

Key Financial Metrics

EPS
−$0.76
est −$0.14 · -442.9%
Revenue
$0.00
est $0.00 · -100.0% YoY
Rating
miss

Key Facts

  • No revenue in Q3 2026 vs $5.4M in Q3 2025
  • Net loss of $44.3M ($0.76/share) vs $7.4M ($0.13/share) in Q3 2025
  • R&D expenses $38.2M, including $35M upfront to Innovent for SP001 license
  • Cash and equivalents $107.9M as of Sep 30, 2026, sufficient into H2 2029
  • SP001 (anti-CD40L antibody) in-licensed from Innovent; Phase 2 in IgG4-RD planned for Q2 2027
  • $105M non-recourse royalty financing closed in July 2026 with HCRx, secured against GSK's Utebzi payments
  • Company has pivoted from anti-infectives (tebipenem HBr) to immune-mediated diseases

Financial Impact

Net loss widened by $36.9M YoY to $44.3M, driven by $35M upfront licensing fee; no revenue vs $5.4M prior year

revenuenet losscash position

Risk Factors

  • No revenue and widening losses; SP001 is still in early clinical development with no approved products
  • Dependence on successful Phase 2 results for SP001; IgG4-RD is a rare disease with limited precedent
  • Future milestone payments from GSK on tebipenem HBr are uncertain and partially encumbered by royalty financing

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-458637
Document: spro-ex99_1.htm0001193125-26-458637
Document: 0001193125-26-458637-index-headers.html0001193125-26-458637
Document: 0001193125-26-458637-index.html0001193125-26-458637
Document: 0001193125-26-458637.txt0001193125-26-458637
8-K Data (Synthetic)0001193125-26-458637

Track record

17 reports on SPRO

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Viewing Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
  2. Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  3. Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
  4. Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
  5. Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
  6. Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  7. Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
  8. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
  9. Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
  10. Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (9h 34m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026